VolitionRx to Present at the 6th Annual LD Micro Conference
NAMUR, Belgium, Nov. 29, 2013 /PRNewswire/ -- VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces it will be presenting at the Sixth Annual LD Micro Conference.
Cameron Reynolds, the CEO of Volition, will provide a company overview and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
The presentation will take place on Wednesday, December 4th at 4 p.m. US Pacific Time at the Luxe Sunset Bel Air Hotel in Los Angeles, California. The webcast can be accessed at: http://wsw.com/webcast/ldmicro5/VNRX
About VolitionRx
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Visit Volition's website (www.volitionrx.com) or connect with us via Twitter, LinkedIn or Facebook.
About the LD Micro Conference
The LD Micro conference hosts over 230 companies in the small cap and micro cap space. The three-day event brings innovative companies together with a tight-knit and loyal investor base. To find out more about the conference, visit the website.
Safe Harbor Statement
Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE VolitionRx Limited
Copyright 2013 PR Newswire
NAMUR, Belgium, Nov. 29, 2013 /PRNewswire/ -- VolitionRx Limited (VNRX:OB), a life sciences company focused on developing blood-based diagnostic tests for different types of cancer, today announces it will be presenting at the Sixth Annual LD Micro Conference.
Cameron Reynolds, the CEO of Volition, will provide a company overview and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
The presentation will take place on Wednesday, December 4th at 4 p.m. US Pacific Time at the Luxe Sunset Bel Air Hotel in Los Angeles, California. The webcast can be accessed at: http://wsw.com/webcast/ldmicro5/VNRX
About VolitionRx
VolitionRx is a life sciences company focused on developing blood-based diagnostic tests for different types of cancer. The tests are based on the science of Nucleosomics which is the practice of identifying and measuring nucleosomes in the bloodstream – an indication that cancer is present.
VolitionRx's goal is to make the tests as common and simple to use, for both patients and doctors, as existing diabetic and cholesterol blood tests. VolitionRx's research and development activities are currently centered in Belgium as the company focuses on bringing its diagnostic products to market first in Europe, then in the US and ultimately, worldwide.
Visit Volition's website (www.volitionrx.com) or connect with us via Twitter, LinkedIn or Facebook.
About the LD Micro Conference
The LD Micro conference hosts over 230 companies in the small cap and micro cap space. The three-day event brings innovative companies together with a tight-knit and loyal investor base. To find out more about the conference, visit the website.
Safe Harbor Statement
Statements in this press release may be "forward-looking statements". Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "optimizing," "potential," "goal," and similar expressions, as they relate to the Company, its business or management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission.
SOURCE VolitionRx Limited
Copyright 2013 PR Newswire
